Advertisement
| car t cell therapy neurotoxicity: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| car t cell therapy neurotoxicity: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele, 2022-02-07 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills. |
| car t cell therapy neurotoxicity: Verbal Perseveration Jacqueline Ann Stark, 2007 Introductory textbooks on neurogenic communication disorders associated with aphasia and brain injury do not provide full documentation of the pervasive influence of perseveration in the diagnosis and treatment of clients with severe language processing deficits. This special issue of Aphasiology aims to revives the profound interest in verbal perseveration observed in the classical German literature between 1890 and 1931. Various aspects of the phenomenon of perseveration are addressed in this issue. When and under what circumstances do perseverations occur? What are the characteristics of perseverative errors and how do they relate to non-perseverative sound and word errors? The papers share a common goal, namely to understand the origin of the phenomenon 'perseveration' in healthy subjects and clients with brain damage and injury. An overarching claim throughout the papers is that perseveration reflects the client's primary language processing deficits. |
| car t cell therapy neurotoxicity: Gene and Cellular Immunotherapy for Cancer Armin Ghobadi, John F. DiPersio, 2022-01-01 Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field. |
| car t cell therapy neurotoxicity: Blood and Marrow Transplant Handbook Richard T. Maziarz, Susan Schubach Slater, 2015-04-20 This updated and expanded edition developed by the Blood and Marrow Stem Cell Transplant team at Oregon Health & Science University Knight Cancer Institute features the latest medical management guidelines and standards of care for hematopoietic stem cell transplant patients. Spanning the timeline from the initial consultation throughout the transplant process, this handbook includes indications for transplantation and donor selection, treatment guidelines for addressing complications during and after transplant, and recommendations for long-term follow up care. Concise, comprehensive, and easy-to-use, Blood and Marrow Transplant Handbook, 2nd Edition presents a multidisciplinary approach to information for physicians and advanced practice medical providers who care for transplant patients, and also residents, fellows, and other trainees. |
| car t cell therapy neurotoxicity: Childhood Acute Lymphoblastic Leukemia Ajay Vora, 2017-04-21 This book provides a comprehensive and up-to-date review of all aspects of childhood Acute Lymphoblastic Leukemia, from basic biology to supportive care. It offers new insights into the genetic pre-disposition to the condition and discusses how response to early therapy and its basic biology are utilized to develop new prognostic stratification systems and target therapy. Readers will learn about current treatment and outcomes, such as immunotherapy and targeted therapy approaches. Supportive care and management of the condition in resource poor countries are also discussed in detail. This is an indispensable guide for research and laboratory scientists, pediatric hematologists as well as specialist nurses involved in the care of childhood leukemia. |
| car t cell therapy neurotoxicity: Jasper's Basic Mechanisms of the Epilepsies Jeffrey Noebels, 2012-06-29 Jasper's Basic Mechanisms, Fourth Edition, is the newest most ambitious and now clinically relevant publishing project to build on the four-decade legacy of the Jasper's series. In keeping with the original goal of searching for a better understanding of the epilepsies and rational methods of prevention and treatment., the book represents an encyclopedic compendium neurobiological mechanisms of seizures, epileptogenesis, epilepsy genetics and comordid conditions. Of practical importance to the clinician, and new to this edition are disease mechanisms of genetic epilepsies and therapeutic approaches, ranging from novel antiepileptic drug targets to cell and gene therapies. |
| car t cell therapy neurotoxicity: Brain Tumor Imaging Elke Hattingen, Ulrich Pilatus, 2015-09-02 This book describes the basics, the challenges and the limitations of state of the art brain tumor imaging and examines in detail its impact on diagnosis and treatment monitoring. It opens with an introduction to the clinically relevant physical principles of brain imaging. Since MR methodology plays a crucial role in brain imaging, the fundamental aspects of MR spectroscopy, MR perfusion and diffusion-weighted MR methods are described, focusing on the specific demands of brain tumor imaging. The potential and the limits of new imaging methodology are carefully addressed and compared to conventional MR imaging. In the main part of the book, the most important imaging criteria for the differential diagnosis of solid and necrotic brain tumors are delineated and illustrated in examples. A closing section is devoted to the use of MR methods for the monitoring of brain tumor therapy. The book is intended for radiologists, neurologists, neurosurgeons, oncologists and other scientists in the biomedical field with an interest in neuro-oncology. |
| car t cell therapy neurotoxicity: Biology and Treatment of Leukemia and Bone Marrow Neoplasms Vinod Pullarkat, Guido Marcucci, 2021-10-09 This book provides a concise update on current understanding of the biology of acute and chronic leukemias and other bone marrow neoplasms, including myelodysplastic and myeloproliferative disorders, and explores new and emerging treatments. There is a particular focus on the molecular abnormalities that are drivers of leukemia and on their detection by modern molecular techniques. Knowledge of the ways in which genomic and metabolic abnormalities in the hematologic neoplasms affect prognosis and treatment decision making is reviewed. Detailed attention is devoted to targeted therapies, including novel drugs, and to potential targets for future drug development. In addition, readers find in-depth discussion of cellular and antibody-based immunotherapies as well as the role of hematopoietic stem cell transplantation in the treatment of leukemias and bone marrow malignancies. The book is of special interest for hematologists, oncologists, and cancer researchers; it is also of value for hematology trainees and medical students. |
| car t cell therapy neurotoxicity: Brain Disorders in Critical Illness Robert D. Stevens, Tarek Sharshar, E. Wesley Ely, 2013-09-19 Brain dysfunction is a major clinical problem in intensive care, with potentially debilitating long-term consequences for post-ICU patients of any age. The resulting extended length of stay in the ICU and post-discharge cognitive dysfunction are now recognized as major healthcare burdens. This comprehensive clinical text provides intensivists and neurologists with a practical review of the pathophysiology of brain dysfunction and a thorough account of the diagnostic and therapeutic options available. Initial sections review the epidemiology, outcomes, relevant behavioral neurology and biological mechanisms of brain dysfunction. Subsequent sections evaluate the available diagnostic options and preventative and therapeutic interventions, with a final section on clinical encephalopathy syndromes encountered in the ICU. Each chapter is rich in illustrations, with an executive summary and a helpful glossary of terms. Brain Disorders in Critical Illness is a seminal reference for all physicians and neuroscientists interested in the care and outcome of severely ill patients. |
| car t cell therapy neurotoxicity: Principles and Practice of Palliative Care and Supportive Oncology Ann M. Berger, John L. Shuster, Jr., Jamie H. Von Roenn, 2012-12-03 Unlike other textbooks on this subject, which are more focused on end of life, the 4th edition of Principles and Practice of Palliative Care and Supportive Oncology focuses on supportive oncology. In fact, the goal of this textbook is to provide a source of both help and inspiration to all those who care for patients with cancer. Written in a more reader-friendly format, this textbook not only offers authoritative and up-to-date reviews of research and clinical care best practices, but also practical clinical applications to help readers put everything they learn to use. |
| car t cell therapy neurotoxicity: Drug Resistance in Leukemia & Gert-Jan L. Kaspers, 1993-01-01 The last ten years have seen the publication of a vast amount of data regarding cellular resistance to drugs in cancer cells. Recent studies have demonstrated that drug resistance assays appear to be predictive of clinical response and suggest that clinicians should now be considering the potential applications of these assays in the treatment of patients with hematological neoplasms. This collection of papers from the International Symposium on the Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma, Amsterdam, 1992, provides a state-of-the-art discussion on drug resistance assays and their role in the design and individualization of treatment protocols. |
| car t cell therapy neurotoxicity: Environmental Neurotoxicology National Research Council, Division on Earth and Life Studies, Commission on Life Sciences, Board on Environmental Studies and Toxicology, Committee on Neurotoxicology and Models for Assessing Risk, 1992-02-01 Scientists agree that exposure to toxic agents in the environment can cause neurological and psychiatric illnesses ranging from headaches and depression to syndromes resembling parkinsonism. It can even result in death at high exposure levels. The emergence of subclinical neurotoxicity-the concept that long-term impairments can escape clinical detection-makes the need for risk assessment even more critical. This volume paves the way toward definitive solutions, presenting the current consensus on risk assessment and environmental toxicants and offering specific recommendations. The book covers: The biologic basis of neurotoxicity. Progress in the application of biologic markers. Reviews of a wide range of in vitro and in vivo testing techniques. The use of surveillance and epidemiology to identify neurotoxic hazards that escape premarket screening. Research needs. This volume will be an important resource for policymakers, health specialists, researchers, and students. |
| car t cell therapy neurotoxicity: Bioreactor Systems for Tissue Engineering Cornelia Kasper, Martijn van Griensven, Ralf Pörtner, 2009-02-03 The editors of this special volume would first like to thank all authors for their excellent contributions. We would also like to thank Prof. Dr. Thomas Scheper, Dr. Marion Hertel and Ulrike Kreusel for providing the opportunity to compose this volume and Springer for organizational and technical support. Tissue engineering represents one of the major emerging fields in modern b- technology; it combines different subjects ranging from biological and material sciences to engineering and clinical disciplines. The aim of tissue engineering is the development of therapeutic approaches to substitute diseased organs or tissues or improve their function. Therefore, three dimensional biocompatible materials are seeded with cells and cultivated in suitable systems to generate functional tissues. Many different aspects play a role in the formation of 3D tissue structures. In the first place the source of the used cells is of the utmost importance. To prevent tissue rejection or immune response, preferentially autologous cells are now used. In particular, stem cells from different sources are gaining exceptional importance as they can be differentiated into different tissues by using special media and supplements. In the field of biomaterials, numerous scaffold materials already exist but new composites are also being developed based on polymeric, natural or xenogenic sources. Moreover, a very important issue in tissue en- neering is the formation of tissues under well defined, controlled and reprod- ible conditions. Therefore, a substantial number of new bioreactors have been developed. |
| car t cell therapy neurotoxicity: Aluminum Neurotoxicity Ankica Jelenković, 2016 Aluminum is the third most abundant element in the Earth's crust. In many of the previous experimental, epidemiological, pathohistological, biochemical and other research studies, aluminum, accumulated from the environment has been recognized as a very harmful substance to the human body. Aluminum intake usually happens unintentionally due to the fact that people know little about its prevalence in water, factory-processed foods, medicines, cosmetics, etc. When accumulated in human organs, it can cause severe damage, and even lead to chronic neurodegenerative diseases. Both oxidative and nitrosative stress can be the leading cause or contribute to its toxic effects in humans and animals. All of this is supported by the fact that mitochondrial dysfunction is the earliest stage of aluminum neurotoxicity. When oxidative damage occurs under the effects of free radicals, together with the decreased antioxidant protection due to the decreased production of the chemical energy molecule (adenosine triphosphate) as well as reducing equivalents (both in and out of mitochondria) then the conditions for the occurrence of a vicious circle in aluminum neurotoxicity are created. Aluminum also significantly interferes with the main steps of the synaptic neurotransmission, which may lead to the progression of neuropathies. The glutamate-glutamine pathway and numerous neurotransmitter transporters are affected as well. Oxidative stress and the disruption of neurotransmission do not only exist when adult individuals are exposed to this neurotoxin, but also in individuals prenatally exposed to it as well, and these are expressed after birth. Numerous research studies, both in animals and humans, ex vivo and in vitro, quite clearly showed that aluminum can be associated with chronic neurodegenerative diseases. Additionally, there is a positive correlation between the exposure to aluminum and the pathophysiology of Alzheimer's, Parkinson's, Huntington's disease, amyotrophic lateral sclerosis, and so on. One of the possible mechanisms for the generation/development of these diseases could be the disturbed homeostasis of essential metals and the appearance of unfolded or misfolded proteins that are mostly specific for a particular disease. In those research studies, the influence of aluminum on the generation of beta-amyloid, alpha synuclein, etc. was satisfactorily examined. It is very difficult, however, to suppress aluminum neurotoxicity, as well as development and progression of the diseases caused by or associated with aluminum. This is the result of some complex mechanisms through which aluminum causes its deleterious effects, and which are also responsible for the existence of multiple targets for aluminum. It is, therefore, necessary to know how these mechanisms induce the damage, in order to be able to prevent or treat the damage once it occurs. A large number of substances, including active components in traditional medicine, medical drugs and substances which are used only experimentally, have been examined so far. The results of studies conducted so far are inconclusive and they require further research. According to all the aforementioned findings, it may be concluded that well-planned, prospective and randomized clinical trials are necessary in order to use any of these substances in humans. |
| car t cell therapy neurotoxicity: Pediatric Neuro-oncology Katrin Scheinemann, Eric Bouffet, 2015-03-26 “The editors...have done an outstanding job of presenting...complex information in a lucid manner – this book is a must-read for the global community of aspiring students and neuro-oncology practitioners.” Amar Gajjar, MD in the Foreword This is a succinct introduction to pediatric neuro-oncology. It summarizes the key advances in molecular biology that have helped transform this rapidly evolving field and provides up-to-date coverage of major and emerging treatment modalities as well as supportive care. Separate chapters present each kind of pediatric brain cancer and its diagnosis and treatment. As more children survive brain cancer, the importance of quality of life issues and helping survivors to cope with the neuropsychological impact and long-term effects of current therapies has come into sharper focus; these topics are also addressed in the book, as are palliative care and pediatric neuro-oncology in countries with limited resources. The book is aimed at trainees and practitioners who seek an up-to-date text in pediatric neuro-oncology that is both comprehensive and concise. |
| car t cell therapy neurotoxicity: Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide Agency for Health Care Research and Quality (U.S.), 2013-02-21 This User’s Guide is a resource for investigators and stakeholders who develop and review observational comparative effectiveness research protocols. It explains how to (1) identify key considerations and best practices for research design; (2) build a protocol based on these standards and best practices; and (3) judge the adequacy and completeness of a protocol. Eleven chapters cover all aspects of research design, including: developing study objectives, defining and refining study questions, addressing the heterogeneity of treatment effect, characterizing exposure, selecting a comparator, defining and measuring outcomes, and identifying optimal data sources. Checklists of guidance and key considerations for protocols are provided at the end of each chapter. The User’s Guide was created by researchers affiliated with AHRQ’s Effective Health Care Program, particularly those who participated in AHRQ’s DEcIDE (Developing Evidence to Inform Decisions About Effectiveness) program. Chapters were subject to multiple internal and external independent reviews. More more information, please consult the Agency website: www.effectivehealthcare.ahrq.gov) |
| car t cell therapy neurotoxicity: Immunopharmacogenomics Yusuke Nakamura, 2015-09-18 This book proposes immunogenomics, or immunopharmacogenomics, as the next-generation big science to uncover the role that the immune system plays in the pathogenesis of many diseases, by summarizing the importance of the deep sequencing of T-cell and B-cell receptors. Immunogenomics/immunopharmacogenomics, a genetic characterization of the immune system made possible by next-generation sequencing (NGS), will be important for the further understanding of the pathogenesis of various disease conditions. Abnormal immune responses in the body lead to development of autoimmune diseases and food allergies. Rejection of recipient cells and tissues, as well as severe immune reactions to donor cells, is also the result of uncontrolled immune responses in the recipient body. There have been many reports indicating that activated immune responses caused by the interaction of drugs and HLA are present in drug-induced skin hypersensitivity and liver toxicity. The importance of the host immune responses has been recognized in cancer treatments, not only for immunotherapy but also for cytotoxic agents and molecular targeted drugs. Hence, characterization of the T-cell receptor and B-cell receptor repertoire by means of NGS deep sequencing will ultimately make possible the identification of the molecular mechanisms that underlie various diseases and drug responses. In addition, this approach may contribute to the identification of antigens associated with the onset or progression of autoimmune diseases as well as food allergies. Although the germline alterations and somatic mutations have been extensively analyzed, changes or alterations of the immune responses during the course of various disease conditions or during various treatments have not been analyzed. It is also clear that computational analyses to draw meaningful inferences of functional recognition receptors on the immune cells remain a huge challenge. |
| car t cell therapy neurotoxicity: Advances in Precision Medicine Oncology Hilal Arnouk, Bassam Abdul Rasool Hassan, 2021 Recent advances in precision medicine and immuno-oncology have led to highly specific and efficacious cancer therapies such as monoclonal antibodies and immune checkpoint inhibitors (ICIs). This book provides an up-to-date overview of advances in the field of immuno-oncology. Chapters cover such topics as ICIs and how they mount a robust immune response against cancer cells as well as the response of ICIs to treatment predictive biomarkers and their potential immune-related adverse events (irAEs). Additionally, the book includes a comprehensive review of the powerful FDA-approved therapeutic agent doxorubicin, highlighting the molecular mechanisms behind doxorubicin's drug resistance and critical side effects. |
| car t cell therapy neurotoxicity: Neurologic Complications of Cancer Lisa M. DeAngelis, Jerome B. Posner, 2009 Patients with cancer can suffer from a bewildering variety of neurologic signs and symptoms. The neurologic symptoms are often more disabling than the primary cancer. Symptoms including confusion, seizures, pain and paralysis may be a result of either metastases to the nervous system or one of several nonmetastatic complications of cancer. The physician who promptly recognizes neurologic symptoms occurring in a patient with cancer and makes an early diagnosis may prevent the symptoms from becoming permanently disabling or sometimes lethal. This monograph, an update of the first edition published in 1995, is divided into 3 sections. The first classifies the wide variety of disorders that can cause neurologic symptoms the patient with cancer, discusses the pathophysiology of nervous system metastases, the pathophysiology and treatment of brain edema and the approach to supportive care of common neurologic symptoms such as seizures, pain, and side effects of commonly used supportive care agents. The second section is devoted to nervous system metastases, addressing in turn, brain, spinal cord, meningeal and cranial and peripheral nerve metastases, describing clinical symptoms, approach to diagnosis and current treatment. The third section addresses several nonmetastatic complications of cancer and includes sections on vascular disease, infections, metabolic and nutritional disorders, side chemotherapy, radiation and other diagnostic and therapeutic procedures. The final chapter addresses paraneoplastic syndromes.The book is intended for practicing oncologists, neurologists, neurosurgeons and radiation oncologists as well as internists who treated patients with cancer. Our attempt was to write a book that would assist oncologists in understanding neurologic problems and neurologists in understanding oncologic problems. The book is also intended for physicians training to specialize in any of the above areas. It includes a practical approach to the diagnosis and management of patients with neurologic disease who are with known to have cancer or in whom cancer is suspected. |
| car t cell therapy neurotoxicity: Co-signal Molecules in T Cell Activation Miyuki Azuma, Hideo Yagita, 2019-11-22 This book equips young immunologists and health professionals with a clear understanding of the fundamental concepts and roles of co-signal molecules and in addition presents the latest information on co-stimulation. The first part of the book is devoted to co-signal molecules and the regulation of T cells. Following an initial overview, subsequent chapters examine each co-signal molecule in turn and discuss the mechanisms by which co-signal molecules regulate the different types of T cell. The second part covers various clinical applications, including in autoimmune disease, neurological disorders, transplantation, graft-versus-host disease, and cancer immunotherapy. To date, co-stimulation blockade and co-inhibition blockade have shown beneficial effects and many additional clinical trials targeting co-signal molecules are ongoing. The mechanisms underlying these successful treatments are explained and the future therapeutic potential in the aforementioned diseases is evaluated. Co-signal Molecules in T Cell Activation will be a valuable reference guide to co-stimulation for basic and clinical researchers in the fields of both immunology and pharmaceutical science. |
| car t cell therapy neurotoxicity: Stem Cells – From Hype to Real Hope Khawaja Husnain Haider, Salim Aziz, MD, 2018-12-17 This book is a compilation of the bench experience of leading experts from various research labs involved in the cutting edge area of research. The authors describe the use of stem cells both as part of the combinatorial therapeutic intervention approach and as tools (disease model) during drug development, highlighting the shift from a conventional symptomatic treatment strategy to addressing the root cause of the disease process. The book is a continuum of the previously published book entitled Stem Cells: from Drug to Drug Discovery which was published in 2017. |
| car t cell therapy neurotoxicity: SITC’s Guide to Managing Immunotherapy Toxicity Marc S. Ernstoff, MD, Igor Puzanov, MD, MSCI, FACP, Caroline Robert, MD, PhD, Adi M. Diab, MD, Peter M. Hersey, MD, PhD, 2019-03-15 The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers. With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care. Key Features: Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy Provides numerous tables that condense and highlight pertinent information for quick reference Describes the various clinical presentations and toxic reactions caused by immunotherapy Purchase includes access to the eBook for use on most mobile devices or computer |
| car t cell therapy neurotoxicity: Progress in Cancer Immunotherapy Shuren Zhang, 2016-05-30 This book provides readers an extensive overview of recent progress in basic and clinical research on cancer immunotherapy. Thanks to rapid advances in molecular biology and immunology, it has become increasingly evident that cancer growth is influenced by host immune responses. With the success of a number of clinical trials, immunotherapy has become a promising treatment modality of cancer. This book covers five major topics, including monoclonal antibodies, biological response modifiers, cancer vaccines, adoptive cellular therapy and oncolytic viruses. It also examines the combination of different immune strategies as well as the combination of immunotherapy with other treatments to increase anti-tumor effects. Through the comprehensive discussion of the topic, the book sheds valuable new light on the treatment of tumors. |
| car t cell therapy neurotoxicity: Oncoimmunology Laurence Zitvogel, Guido Kroemer, 2017-12-13 In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. |
| car t cell therapy neurotoxicity: Immune Regulation Marc Feldmann, N. A. Mitchison, 2012-12-06 Leukocyte culture conferences have a long pedigree. This volume records some of the scientific highlights of the 16th such annual con ference, and is a witness to the continuing evolution and popularity of leukocyte culture and of immunology. There is strong evidence of the widening horizons of immunology, both technically, with the obviously major impact of molecular biology into our understanding of cellular processes, and also conceptually. Traditionally, the 'proceedings' of these conferences have been published. But have the books produced really recorded the major part of the conference, the informal, friendly, but intense and some times heated exchanges that take place between workers in tackling very similar problems and systems and which are at the heart of every successful conference? Unfortunately this essence cannot be incorpo rated by soliciting manuscripts. For this reason, we have changed the format of publication, retaining published versions of the symposium papers, but requesting the workshop chairmen to produce a summary of the major new observations and areas of controversy highlighted in their sessions, as a vehicle for defining current areas of interest and debate. Not an easy task, as the workshop topics were culled from the abstracts submitted by the participants, rather than being on predefined topics. The unseasonal warmth in Cambridge was reflected in the atmos phere of the conference, the organization of which benefited from the administrative skills of Jean Bacon, Philippa Wells, Mr. Peter Irving, and Mrs. |
| car t cell therapy neurotoxicity: Autoimmune Neurology , 2016-03-11 Autoimmune Neurology presents the latest information on autoimmune neurologic disease, the immune response to the body where organs run wild, causing the immune system to attack itself. Autoimmunity is a main element in numerous nervous system diseases and can target any structure within the central or peripheral nervous system. Over the past 20 years, significant advances in our understanding of the pathophysiology of autoimmune disorders, including the use of biomarkers has led to new diagnosis and treatment options. Neurologic conditions associated with autoimmune reactions include dementia, neuromuscular disease, epilepsy, sleep disorders, diabetes, and other common neurologic disorders and disease. This current tutorial-reference will be a must-have title for clinical neurologists, research neurologists, neuroscientists, and any medical professional working with autoimmune disease and disorders. - Includes comprehensive coverage of autoimmune neurology - Details the latest techniques for the study, diagnosis, and treatment of diseases and disorders, including dementia, neuromuscular disease, epilepsy, and sleep disorders - Presents a focused reference for clinical practitioners and the clinical neurology and neurology research communities |
| car t cell therapy neurotoxicity: Immunotherapy of Hepatocellular Carcinoma Tim F. Greten, 2018-08-22 In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients. |
| car t cell therapy neurotoxicity: Hospitalist Neurology Martin A. Samuels, 1999 Hospitalist Neurology, in the highly regarded Blue Books of Practical Neurology series, focuses on the clinical practice of in-patient neurology as well as the neurologic sequelae of non-neurologic conditions of hospitalized patients. It is meant to provide consulting hospital-based neurologists with a rational approach to evaluating neurological problems in a busy general hospital. |
| car t cell therapy neurotoxicity: Advances in childhood leukemia , 1982 |
| car t cell therapy neurotoxicity: Successful Drug Discovery, Volume 5 Janos Fischer, Christian Klein, Wayne E. Childers, 2021-02-12 Filled with unique insights into current drugs that have made it to the marketplace In the fifth volume of Successful Drug Discovery, the inventors and primary developers of drugs that made it to the market tell the story of the drugs discovery and development. Case studies of drugs from different therapeutic fields reveal the all-too-often unpredictable path from the first drug candidate molecule to the successfully marketed drug. In addition, this new volume addresses overarching topics for drug discovery, such as drug discovery in academia, and discusses currently important classes of small molecule as well as biological drugs. Comprehensive in scope, the books nine chapters provide a representative cross-section of the present-day drug development effort. The authoritative fifth volume is filled with relevant data and chemical information, as well as the insight and experience of the best contemporary drug creators. This important volume: - Puts the focus on recently introduced drugs that have not yet made it into standard textbooks or general references - Contains information and insight that is new and often not even available from the primary literature - Reveals what it takes to successfully develop a drug molecule that has made it all the way to the market - Is endorsed and supported by the International Union of Pure and Applied Chemistry (IUPAC) Written for medicinal chemists, pharmaceutical chemists, organic chemists, Successful Drug Discovery, Volume Five reveals the most recent techniques used by drug innovators in the drug development process. |
| car t cell therapy neurotoxicity: Digital Economy. Emerging Technologies and Business Innovation Rim Jallouli, Mohamed Anis Bach Tobji, Deny Bélisle, Sehl Mellouli, Farid Abdallah, Ibrahim Osman, 2019-09-20 This book constitutes the refereed proceedings of the 4th International Conference on Digital Economy, ICDEc 2019, held in Beirut, Lebanon, in April 2019. The conference was founded in 2016 to discuss innovative research and projects related to the support role of Information System Technologies in the digital transformation process, business innovation and e-commerce. The 31 papers presented in this volume were carefully reviewed and selected from 89 submissions. The theme of ICDEc 2019 was “Digital Economy: Emerging Technologies and Business Innovation”. The papers were organized in topical sections named: digital transformation; e-finance; social media communication; intelligent systems; e-commerce and business analytics; e-learning and cloud education; e-commerce and digital economy; data science; digital marketing; and digital business model. |
| car t cell therapy neurotoxicity: Natural Killer Cells Srinivas S. Somanchi, 2016-05-13 This volume contains collection of Natural Killer Cell methodologies relevant for both basic and translational research. These methodologies present new developments in the natural killer (NK) cell field, such as understanding the influence of NK cells metabolism on its function, identifying complexity of NK cell subsets through mass cytometry, and determining the emergence of memory NK cells in murine model of MCMV infection. Methods that study NK cell migration and cytotoxicity through endpoint analysis or live single cell imaging are also discussed. Chapters also describe methods pertaining to translational application of NK cells, such as ex vivo expansion of NK cells on K562 cell lines genetically modified to express either membrane bound IL-15 or membrane bound IL-21, large scale NK cell culture, current techniques for engineering NK cells to express chimeric antigen receptors or chemokine receptors using retroviral vectors, electroporation of mRNA, and the natural phenomenon of trogocytosis. Written in the highly successful Methods in Molecular Biology series format, these chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting edge and thorough, Natural Killer Cells: Methods and Protocols is a valuable resource for researchers who not only want to understand mechanisms that govern NK cell behavior and diversity, but also for those who want to understand how to systematically evaluate NK cells for adoptive immunotherapy applications. |
| car t cell therapy neurotoxicity: Guide to Immunotherapy Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2018-10 |
| car t cell therapy neurotoxicity: Cognition and Cancer Christina A. Meyers, James R. Perry, 2012-12-13 This book is a unique resource on the influence cancer and cancer treatments have on cognition. The majority of cancer patients on active treatment experience cognitive impairments often referred to as 'chemobrain' or 'chemofog'. In addition, patients with primary or metastatic tumors of the brain often experience direct neurologic symptoms. This book helps health care professionals working with cancer patients who experience cognitive changes and provides practical information to help improve care by reviewing and describing brain-behavior relationships; research-based evidence on cognitive changes that occur with various cancers and cancer treatments; assessment techniques, including neurocognitive assessment and neuroimaging techniques; and intervention strategies for affected patients. In short, it will explain how to identify, assess and treat these conditions. |
| car t cell therapy neurotoxicity: Understanding and Managing Oncologic Emergencies Marcelle Kaplan, 2018 Thoroughly updated and expanded, the third edition of Understanding and Managing Oncologic Emergencies: A Resource for Nurses is a comprehensive yet practical guide to understanding and managing oncologic emergencies from the nursing perspective. |
| car t cell therapy neurotoxicity: Cancer Immunotherapy Principles and Practice Lisa H. Butterfield, Howard L. Kaufman, Francesco M. Marincola, 2017 Part 1: Intratumoral Signatures Associated With Immune Responsiveness |
| car t cell therapy neurotoxicity: NEJM Clinical Problem Solving Sanjay Saint, Jeffrey M. Drazen, Caren Solomon, 2006-05-09 Expert clinical problem-solving methods and guidance—from the editors and contributors of the New England Journal of Medicine This invaluable resource from the New England Journal of Medicine expertly addresses methods and challenges in clinical diagnosis. Including the peer-reviewed content of the NEJM’s renowned “Clinical Problem Solving” feature, this powerful resource is packed with case discussions from both ambulatory and hospital practice. Each Case Presentation reveals thought-provoking clinical and laboratory clues as the diagnostic considerations begin to emerge. Subsequent clinical detail and discussion and expert analysis add to the diagnostic picture until a final clinical diagnosis is reached. New England Journal of Medicine: Clinical Problem-Solving features: Published cases drawn from the New England Journal of Medicine reflecting actual patient-management situations that physicians experience in their everyday clinical practice Two brand new, never-before-published chapters on medical decision-making skills and methods Wide-ranging coverage of the major considerations in each case, from underlying pathophysiology to signs from the physical examination to lab testing strategies More than 100 full-color illustrations, tables, and algorithms Meticulously selected references that open up avenues for further study And much more! From cover to cover, New England Journal of Medicine: Clinical Problem-Solving presents the best case analysis, diagnostic thought processes, and problem-solving-- direct from master clinicians. |
| car t cell therapy neurotoxicity: Medication-Induced Movement Disorders Joseph H. Friedman, 2020-05-07 Medications that may produce movement disorders are widely used. The resulting disorders are often highly disconcerting for the patient and their relatives, especially when the connection between medication and disorder is not recognized. However, ascribing an adverse drug effect to medication exposure is often difficult, especially when the side effect is rare. Covering various drugs - including the major classes of medications working primarily on the brain, specifically antipsychotics and antidepressants - this all-encompassing review of medication-induced movement disorders aids early recognition and improved treatment. The problem of what to do when the offending medication cannot be reduced is also reviewed. It discusses the best options for evaluation and treatment, including medical imaging and deep brain stimulation, and guides the clinician in managing the disorder, making this a vital reference for medical specialists and consultants in neurology and neuropharmacology and any clinician seeing patients on medications crossing the blood brain barrier. |
| car t cell therapy neurotoxicity: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice MiKaela M. Olsen, Kristine B. LeFebvre, Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2022 Oncology nursing is a unique specialty that requires continuous learning to stay up to date on cancer pathophysiology, cutting-edge drugs, and the evidence-based management of cancer and cancer treatment-related toxicities. The Oncology Nursing Society's (ONS's) second edition of Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice provides nurses with the tools to understand how medications are used in cancer treatment, the effect of medication-related toxicities, and evidence-based recommendations to manage and treat these toxicities. This edition features many new cancer therapies approved since the 2019 publication. Each drug is categorized as chemotherapy, hormone, targeted, or immunotherapy agents. Extensive drug tables in the book provide nurses with tips for managing patients receiving these drugs. The expansion of oral antineoplastic therapies, alone or in combination with infusion therapy, requires that nurses review a patient's complete cancer treatment plan and consider the side effects, toxicities, and adherence to oral drugs to ensure patient tolerance and efficacy. This second edition has seen content expanded on the topic of genomics as we move forward in the world of personalized oncology. Health equity is approached with information discussing financial distress, cultural disparities, and health literacy. The latest guidelines and recommendations for treatment, symptom management, and survivorship have been integrated into this new text. This edition features a QR code, provided with the purchase of this book, to download quarterly drug updates. You will see new evidence related to many aspects of cancer nursing care incorporated into this edition, such as hypersensitivity response, safe handling of hazardous drugs, and more. The editors want to thank all of the contributors to this edition who worked tirelessly, despite a pandemic, to make this new edition a reality. This work builds on the knowledge of many generations of oncology nurses and has been used nationally and internationally to guide oncology nursing practice. We are proud to continue to serve oncology nurses worldwide with an essential resource to guide their practice-- |
Assessing and Management of Neurotoxicity After CAR-T Therapy …
CAR-T cell therapy is associated with potentially life-threatening toxicities such as cytokine release syndrome (CRS) and neurotoxicity (NT). While CRS pathophysiology and …
CAR T-Cell Associated Neurotoxicity: Mechanisms ... - PubMed
Jul 1, 2019 · Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary new form of immunotherapy for the treatment of hematologic malignancies. The two primary toxicities …
CAR T-cell-associated neurotoxicity: A comprehensive review
Nov 1, 2024 · We here provide a review of neurological adverse events observed in patients undergoing CAR T-cell therapy, focusing on their incidence, clinical manifestations, underlying …
Management of Immune Effector Cell-Associated Neurotoxicity …
Feb 7, 2022 · ICANS is a common and usually reversible toxicity of CAR-T cell therapy, occurring within a week of infusion, often after cytokine release syndrome. ICANS is a clinical …
Neurotoxicity—CAR T-cell therapy: what the neurologist needs …
Clinical studies have shown that a single dose of CAR T-cells can deliver durable clinical remissions for some patients with B-cell cancers where conventional therapies have failed. …
Incidence and management of CAR-T neurotoxicity in patients …
Feb 24, 2022 · In CARTITUDE-1, 5% of patients with MM reported movement and neurocognitive treatment-emergent adverse events (MNTs) with ciltacabtagene autoleucel (cilta-cel), a B-cell …
Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy
Chimeric antigen receptor (CAR) T-cell therapy has revolutionised the treatment of haematological malignancies and has demonstrated efficacy in early trials for solid tumours, …
Clinical presentation, management, and biomarkers of neurotoxicity ...
May 16, 2019 · Chimeric antigen receptor (CAR) T cells have emerged as a promising class of cell-based immunotherapy in refractory malignancies. Neurotoxicity represents a common and …
Neurological updates: neurological complications of CAR-T therapy
However, neurological toxicity is a common complication of CAR-T cell therapy, seen in over 50% of recipients in some cohorts. Since 2018, the term immune effector cell-associated …
CAR-T cell Therapy: Side-effects and neurotoxicity
Apr 2, 2019 · Learn more about how CAR-T affects the immune system and a side-effect similar to delirium called neurotoxicity. Neurotoxicity can routinely cause difficulties with: Attention; …
Description of neurotoxicity in a series of patients treated with CAR T …
Nov 4, 2020 · Neurotoxicity associated with CAR T-cell therapies occurs in more than 40% of patients. The clinical pattern is heterogeneous but cognitive disorders (not limited to language …
How I treat unique and difficult-to-manage cases of CAR T-cell therapy ...
May 18, 2023 · In this study, we present 3 scenarios of patients treated with CAR T cells who develop unique types of neurotoxicity, and we describe an approach for the evaluation and …
Neurotoxicity-CAR T-cell therapy: what the neurologist needs ... - PubMed
Parallel investigation to exclude other central nervous system pathologies (infection, disease progression) is critical. In this review, we discuss current paradigms around CAR T-cell …
CAR T-cell-associated neurotoxicity in central nervous system ...
CAR T-cell-associated neurotoxicity—initially defined as CAR T-cell-related encephalopathy syndrome (CRES) and currently coined within the acronym ICANS (immune effector cell …
CAR T-cell therapy - Cancer Research UK
CAR T-cell therapy is a type of immunotherapy. It's also called a type of adoptive cell transfer. ... Doctors call this neurotoxicity. This is also known as immune effector cell associated …
Efficacy and safety of a novel CD19, CD22 dual-targeted fully …
Jun 5, 2025 · Background Chimeric antigen receptor (CAR) T-cell therapies targeting CD19 have demonstrated promising efficacy in treating refractory or relapsed B-cell malignancies. …
The neurological toll of CAR T cell therapy - ScienceDirect
4 days ago · In this issue of Cell, Geraghty and Acosta-Alvarez et al. explore neurological deficits in cancer-bearing mice treated with CAR T cell therapy to determine the underlying biological …
Johnson & Johnson's dual-targeting CAR T-cell therapy shows …
2 days ago · Two patients had immune effector cell-associated neurotoxicity syndrome (ICANS), one Grade 1 and one Grade 3. ... (CAR) T-Cell Therapy, In Patients (Pts) With …
CAR-T–cell neurotoxicity: hope is on the horizon Free
May 16, 2019 · In this issue of Blood, Karschnia et al spotlight the “Achilles heel” of chimeric antigen receptor (CAR) T-cell therapy and call for prospective clinical trials to evaluate …
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
Acute neurologic signs and/or symptoms occur in a significant proportion of patients treated with CD19-directed chimeric antigen receptor-T cells for B-cell malignancies. Clinical …
The neurological toll of CAR T cell therapy - Cell Press
4 days ago · Understanding acute and long-term adverse events following CAR T cell therapy for cancer remains a crucial area of investigation as CAR T cells become more prominent in the …
Neurological Complications of CAR T Cell Therapy - PubMed
Jul 1, 2020 · Neurotoxicity affects approximately half of patients treated with CAR T cells and can cause severe morbidity. We discuss the incidence, pathophysiology, and management of …
CAR T Cell Therapy - Penn Medicine
CAR T cell therapy is a highly effective method of treating certain types of cancer. However, like any medical procedure, it may cause some side effects or complications. One of the potential …
CAR T-cell-associated neurotoxicity: A comprehensive review
We here provide a review of neurological adverse events observed in patients undergoing CAR T-cell therapy, focusing on their incidence, clinical manifestations, underlying mechanisms and …
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell …
Neurotoxicity, another common toxicity related to CAR T-cell therapy, is a toxic encephalopathy state with a broad spectrum of neuropsychiatric symptoms. Such neurotoxicity has been …
The neurological toll of CAR T cell therapy - PubMed
4 days ago · Understanding acute and long-term adverse events following CAR T cell therapy for cancer remains a crucial area of investigation as CAR T cells become more prominent in the …
Neurological updates: neurological complications of CAR-T therapy
Mar 3, 2021 · However, neurological toxicity is a common complication of CAR-T cell therapy, seen in over 50% of recipients in some cohorts. Since 2018, the term immune effector cell …
Aging alters the response to CAR T cell therapy - Nature Cancer
4 days ago · A review discussing the possible influence of aging on the efficacy of CAR T cell therapy. Article CAS PubMed Google Scholar Georgiev, P. et al. Age-associated contraction …
Assessing and Management of Neurotoxicity After CAR-T Therapy …
CAR-T cell therapy is associated with potentially life-threatening toxicities such as cytokine release syndrome (CRS) and neurotoxicity (NT). While CRS pathophysiology and management are well …
CAR T-Cell Associated Neurotoxicity: Mechanisms ... - PubMed
Jul 1, 2019 · Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary new form of immunotherapy for the treatment of hematologic malignancies. The two primary toxicities …
CAR T-cell-associated neurotoxicity: A comprehensive review
Nov 1, 2024 · We here provide a review of neurological adverse events observed in patients undergoing CAR T-cell therapy, focusing on their incidence, clinical manifestations, underlying …
Management of Immune Effector Cell-Associated Neurotoxicity …
Feb 7, 2022 · ICANS is a common and usually reversible toxicity of CAR-T cell therapy, occurring within a week of infusion, often after cytokine release syndrome. ICANS is a clinical …
Neurotoxicity—CAR T-cell therapy: what the neurologist needs …
Clinical studies have shown that a single dose of CAR T-cells can deliver durable clinical remissions for some patients with B-cell cancers where conventional therapies have failed. A significant …
Incidence and management of CAR-T neurotoxicity in patients …
Feb 24, 2022 · In CARTITUDE-1, 5% of patients with MM reported movement and neurocognitive treatment-emergent adverse events (MNTs) with ciltacabtagene autoleucel (cilta-cel), a B-cell …
Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy
Chimeric antigen receptor (CAR) T-cell therapy has revolutionised the treatment of haematological malignancies and has demonstrated efficacy in early trials for solid tumours, neurological and …
Clinical presentation, management, and biomarkers of neurotoxicity …
May 16, 2019 · Chimeric antigen receptor (CAR) T cells have emerged as a promising class of cell-based immunotherapy in refractory malignancies. Neurotoxicity represents a common and …
Neurological updates: neurological complications of CAR-T therapy
However, neurological toxicity is a common complication of CAR-T cell therapy, seen in over 50% of recipients in some cohorts. Since 2018, the term immune effector cell-associated neurotoxicity …
CAR-T cell Therapy: Side-effects and neurotoxicity
Apr 2, 2019 · Learn more about how CAR-T affects the immune system and a side-effect similar to delirium called neurotoxicity. Neurotoxicity can routinely cause difficulties with: Attention; …
Description of neurotoxicity in a series of patients treated with CAR T …
Nov 4, 2020 · Neurotoxicity associated with CAR T-cell therapies occurs in more than 40% of patients. The clinical pattern is heterogeneous but cognitive disorders (not limited to language …
How I treat unique and difficult-to-manage cases of CAR T-cell therapy …
May 18, 2023 · In this study, we present 3 scenarios of patients treated with CAR T cells who develop unique types of neurotoxicity, and we describe an approach for the evaluation and …
Neurotoxicity-CAR T-cell therapy: what the neurologist needs ... - PubMed
Parallel investigation to exclude other central nervous system pathologies (infection, disease progression) is critical. In this review, we discuss current paradigms around CAR T-cell therapy, …
CAR T-cell-associated neurotoxicity in central nervous system ...
CAR T-cell-associated neurotoxicity—initially defined as CAR T-cell-related encephalopathy syndrome (CRES) and currently coined within the acronym ICANS (immune effector cell …
CAR T-cell therapy - Cancer Research UK
CAR T-cell therapy is a type of immunotherapy. It's also called a type of adoptive cell transfer. ... Doctors call this neurotoxicity. This is also known as immune effector cell associated …
Efficacy and safety of a novel CD19, CD22 dual-targeted fully …
Jun 5, 2025 · Background Chimeric antigen receptor (CAR) T-cell therapies targeting CD19 have demonstrated promising efficacy in treating refractory or relapsed B-cell malignancies. …
The neurological toll of CAR T cell therapy - ScienceDirect
4 days ago · In this issue of Cell, Geraghty and Acosta-Alvarez et al. explore neurological deficits in cancer-bearing mice treated with CAR T cell therapy to determine the underlying biological …
Johnson & Johnson's dual-targeting CAR T-cell therapy shows …
2 days ago · Two patients had immune effector cell-associated neurotoxicity syndrome (ICANS), one Grade 1 and one Grade 3. ... (CAR) T-Cell Therapy, In Patients (Pts) With …
CAR-T–cell neurotoxicity: hope is on the horizon Free
May 16, 2019 · In this issue of Blood, Karschnia et al spotlight the “Achilles heel” of chimeric antigen receptor (CAR) T-cell therapy and call for prospective clinical trials to evaluate strategies to …
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
Acute neurologic signs and/or symptoms occur in a significant proportion of patients treated with CD19-directed chimeric antigen receptor-T cells for B-cell malignancies. Clinical manifestations …
The neurological toll of CAR T cell therapy - Cell Press
4 days ago · Understanding acute and long-term adverse events following CAR T cell therapy for cancer remains a crucial area of investigation as CAR T cells become more prominent in the …
Neurological Complications of CAR T Cell Therapy - PubMed
Jul 1, 2020 · Neurotoxicity affects approximately half of patients treated with CAR T cells and can cause severe morbidity. We discuss the incidence, pathophysiology, and management of …
CAR T Cell Therapy - Penn Medicine
CAR T cell therapy is a highly effective method of treating certain types of cancer. However, like any medical procedure, it may cause some side effects or complications. One of the potential …
CAR T-cell-associated neurotoxicity: A comprehensive review
We here provide a review of neurological adverse events observed in patients undergoing CAR T-cell therapy, focusing on their incidence, clinical manifestations, underlying mechanisms and …
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell …
Neurotoxicity, another common toxicity related to CAR T-cell therapy, is a toxic encephalopathy state with a broad spectrum of neuropsychiatric symptoms. Such neurotoxicity has been …
The neurological toll of CAR T cell therapy - PubMed
4 days ago · Understanding acute and long-term adverse events following CAR T cell therapy for cancer remains a crucial area of investigation as CAR T cells become more prominent in the …
Neurological updates: neurological complications of CAR-T therapy
Mar 3, 2021 · However, neurological toxicity is a common complication of CAR-T cell therapy, seen in over 50% of recipients in some cohorts. Since 2018, the term immune effector cell-associated …
Aging alters the response to CAR T cell therapy - Nature Cancer
4 days ago · A review discussing the possible influence of aging on the efficacy of CAR T cell therapy. Article CAS PubMed Google Scholar Georgiev, P. et al. Age-associated contraction of …
